Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × HER2-negative Breast Cancer × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 357 Colorectal Neoplasms 271 Rectal Neoplasms 193 Stomach Neoplasms 183 Pancreatic Neoplasms 120 Neoplasm Metastasis 113 Colonic Neoplasms 82 Neoplasms 78 Triple Negative Breast Neoplasms 55 Esophageal Neoplasms 52 Nasopharyngeal Carcinoma 34 Biliary Tract Neoplasms 33 Cholangiocarcinoma 29 Adenocarcinoma 29 Gallbladder Neoplasms 27 Carcinoma, Hepatocellular 25 Bile Duct Neoplasms 20 Adenocarcinoma Of Esophagus 20 Locally Advanced Rectal Cancer 18 Brain Neoplasms 18 Carcinoma, Non-Small-Cell Lung 16 Squamous Cell Carcinoma of Head and Neck 15 Head and Neck Neoplasms 15 Liver Neoplasms 14 Gastrointestinal Neoplasms 14 Esophageal Squamous Cell Carcinoma 14 Colorectal Cancer Metastatic 14 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Ovarian Neoplasms 12 Carcinoma, Renal Cell 12

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡